9 completed, 1 active not recruiting. 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 5 | Completed 4, Active not recruiting 1 |
Follow Recurrent Childhood Malignant Germ Cell Tumor: new trials by email Literature Review of Recurrent Childhood Malignant Germ Cell Tumor trials Research Report on Recurrent Childhood Malignant Germ Cell Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma | Phase 2 | Completed | Children's Oncology Group | 118 | 2011-02-01 | 2020-05-13 |
| Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma vorinostat, bortezomib, pharmacological study - Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2009-08-01 | 2013-07-02 |
| Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors Carboplatin, Filgrastim, Ifosfamide - Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Malignant Germ Cell Tumor | Phase 2 | Completed | Children's Oncology Group | 20 | 2007-11-05 | 2018-08-29 |
| Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor busulfan, melphalan, topotecan hydrochloride - Solid Tumor, Adult Central Nervous System Germ Cell Tumor | Phase 1 | Completed | City of Hope Medical Center | 25 | 2007-02-26 | 2025-03-20 |
| Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas irinotecan hydrochloride, oxaliplatin - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2005-03-01 | 2013-06-05 |
| Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment oxaliplatin - Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 180 | 2004-10-01 | 2013-06-05 |
| Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors erlotinib hydrochloride, temozolomide, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 95 | 2004-02-01 | 2013-06-05 |
| Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas alvocidib, pharmacological study - Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2001-04-01 | 2013-07-02 |
Familial ependymoma (8) · Neuroblastoma (8) · Medulloblastoma (7) · Neuroectodermal Tumors, Primitive, Peripheral (7) · Astrocytoma (6) · Osteosarcoma (6) · Optic Nerve Glioma (5) · Wilms Tumor (5) · Hepatoblastoma (4) · Burkitt Lymphoma (3) · Dendritic Cell Sarcoma, Interdigitating (3) · Recurrence (3) · Testicular Neoplasms (3) · Central Nervous System Neoplasms (2) · Colonic Neoplasms (2)
Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms, Germ Cell and Embryonal (10) · Neoplasms, Glandular and Epithelial (9) · Neoplasms, Nerve Tissue (9) · Neoplasms, Neuroepithelial (9) · Neuroectodermal Tumors (9) · Neuroectodermal Tumors, Primitive (9) · Neoplasms by Site (8) · Male Urogenital Diseases (7) · Neoplasms, Bone Tissue (7) · Neoplasms, Complex and Mixed (7) · Neoplasms, Connective Tissue (7) · Neoplasms, Connective and Soft Tissue (7) · Nervous System Diseases (7)
Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Oxaliplatin (2) · Biopsy (1) · Bone Marrow Transplantation (1) · Bortezomib (1) · Busulfan (1) · Carboplatin (1) · Erlotinib Hydrochloride (1) · Ifosfamide (1) · Irinotecan (1) · MLN 8237 (1) · Magnetic Resonance Spectroscopy (1) · Melphalan (1) · Nuclear Medicine Department, Hospital (1)
National Cancer Institute (NCI) (7) · Children's Oncology Group (2) · City of Hope Medical Center (1)
United States (10) · Puerto Rico (3) · Canada (2) · Australia (1)
Alice Lee (1) · Anna Pawlowska, MD (1) · Carlos Rodriguez-Galindo (1) · James Whitlock (1) · Jodi Muscal (1) · Julia Glade-Bender (1) · Lisa McGregor (1) · Orren Beaty (1) · Regina Jakacki (1) · Yael Mosse (1)
PMID 31401903, PMID 30777875, PMID 34435684, PMID 38815151
U01CA097452 (4), U10CA098543 (3), U10CA180886 (2), UM1CA081457 (1)